Memantine transdermal patch

Drug Profile

Memantine transdermal patch

Alternative Names: Corplex™ memantine transdermal patch; Memantine transdermal patch - Corium International

Latest Information Update: 29 Sep 2016

Price : $50

At a glance

  • Originator Corium International
  • Class Amines; Analgesics; Antidementias; Antiparkinsonians; Antispastics; Antitussives; Organic bridged compounds; Small molecules
  • Mechanism of Action NMDA receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Phase I Alzheimer's disease

Most Recent Events

  • 13 Sep 2016 Corium completes a phase-I clinical trial in Alzheimer's disease in USA (Transdermal) (ACTRN12616000349448)
  • 24 Aug 2016 US FDA provides positive pre-IND feedback for Memantine transdermal for Alzheimer's disease
  • 15 Mar 2016 Biomarkers information updated
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top